“Thanks for bringing this to the state of Indiana to help students here, Hoosiers here focus on fitness and health and their wellness,” Gov. Eric Holcomb said in the recent video ribbon cutting. “Obviously it’s important every year, but it could not be more important right now.”
Quest Diagnostics and Catapult Health Provide Virtual Preventive Care Services for Employers During COVID-19 Pandemic and Beyond
First collaboration of virtual care provider and national laboratory provider features self-collected at-home specimen collection and mental health care support to empower diverse workforces to access health care safely
Clinical encounter also evaluates patients for risk of COVID-19
SECAUCUS, N.J., Oct. 27, 2020 /PRNewswire/ — Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, and Catapult Health, the leading national provider of employer-sponsored Preventive Checkups, have formed a collaboration designed to help organizations facilitate virtual (telehealth) access to clinical services for their employees and adult dependents, with emphasis on reducing risks related to preventable chronic diseases.
The first-of-its-kind collaboration specifically focuses on helping employers create a highly convenient and safe way for employees to access thorough and guideline driven preventive care and mental health support during the COVID-19 pandemic. Research shows many individuals are reluctant to seek in-person health care due to fear of contracting the SARS-CoV-2 virus, raising the prospect that untreated, preventable conditions will progress to more advanced disease.
“Social distancing and fear of contracting COVID-19 make it difficult for many individuals to access preventive care services from their healthcare providers. At the same time, employers recognize that at-home care, technology enabled options, including preventive care and screening, can be highly effective in enabling prevention and treatment of chronic diseases, supporting better workforce health and lower medical costs,” said Jay G. Wohlgemuth, M.D., Senior Vice President and Chief Medical Officer, and head of the company’s Employer Population Health programs. “Quest Diagnostics and Catapult Health have complementary capabilities that, together, will improve the ability of organizations to support their employees’ health by providing a patient-centric service that meets them where they are during the pandemic and beyond.”
The collaboration pairs insights from Quest’s biometric screenings offered at-home via specimen self-collection, at Quest’s Patient Service Centers, and at the worksite with Catapult Health’s new VirtualCheckup™ solution. The VirtualCheckup includes a video preventive care checkup to allow for confidential analysis and consultation with a nurse practitioner. Each checkup covers personal and family health history, Quest’s lab test and biometric data, prescription drug adherence, depression screening (PHQ-9), and concludes with the creation of a personal action plan to include referral into employer health and benefits programs. The consultation also screens for potential COVID-19 exposure, and individuals identified as at-risk may be directed to COVID-19 diagnostic testing services provided by Quest.
Health plans typically reimburse Catapult’s preventive care checkups as a covered annual preventive checkup, reducing medical costs for employers and the need for employees to visit a doctor for the checkup.
“When people skip doctor visits, the consequences can be grave in terms of poorer long-term outcomes and higher medical costs,” said David Michel, CEO of Catapult Health. “Because they sponsor much of the nation’s healthcare, employers end up absorbing these costs to a great degree. Our unique virtual care model is designed to change that by taking preventive care into employee’s homes, thereby solving for access
Eloxx Presents Two Preclinical Posters at the 2020 North American Cystic Fibrosis Virtual Conference
WALTHAM, Mass., Oct. 22, 2020 (GLOBE NEWSWIRE) — Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that it presented data from two scientific abstracts at the North American Cystic Fibrosis Virtual Conference (NACFC). The two abstracts were also showcased in the NACFC virtual poster gallery and electronically published as a supplement to Pediatric Pulmonology. The live sessions and discussions will take place through October 23rd, 2020. These virtual posters are available to registered attendees on the NACFC online conference platform.
“We were pleased to have the opportunity to present additional preclinical study results in cystic fibrosis at the 2020 NACFC virtual conference that demonstrate ELX-02’s selectivity for read-through of premature stop codons versus native stop codons and its ability to restore production of functional CFTR in patient-derived organoids,” said Dr. Gregory Williams, Chief Executive Officer of Eloxx Pharmaceuticals. “We believe that these results de-risk the current Phase 2 proof of concept clinical trials for ELX-02 in cystic fibrosis. We are continuing to advance our trials in Europe, Israel and the U.S., and we look forward to reporting top line data from the Phase 2 clinical trial program as quickly as possible.”
The details for the two ELX-02 poster presentations are:
Poster Session Presentation Title: “ELX-02 Generates Protein Via Premature Stop Codon Read-through Without Inducing Native Stop Codon Read-through Proteins”
Poster #: 433
Presenter: Dr. Dan Crawford, Eloxx Pharmaceuticals
ELX-02 produces significant read-through of premature stop codons leading to full length proteins, demonstrated using DMS-114 cells with the R213X nonsense mutation in the TP53 gene.
Using three complementary techniques, no evidence of native stop codon read-through products could be detected. These data suggest that ELX-02 does not promote native stop codon read-through at concentrations relevant to premature stop codon read-though.
The results of studies are consistent with the acceptable tolerability profile of ELX-02 across preclinical and clinical studies to date.
Poster Session Presentation Title: “CFTR Restoration By ELX-02 Across CF Nonsense Genotypes: Utilizing Patient-Derived Organoids to Survey Responsive Alleles”
Poster #: 383
Presenter: Dr. Matthew Goddeeris, Eloxx Pharmaceuticals
The patient-derived organoid CFTR FIS assay has enabled the screening of a wide selection of cystic fibrosis nonsense alleles representing >75% of the cystic fibrosis nonsense population. Using this method, we continue to identify new responsive genotypes.
The response of W1282X patient-derived organoids to ELX-02 mediated through read-through positively correlates with CFTR mRNA expression.
Increasing the available CFTR mRNA pool through inhibition of nonsense mediated decay has a synergistic effect on ELX-02 mediated functional CFTR read-through.
These results help guide the interpretation of the patient-derived organoid CFTR FIS assay data by highlighting the importance of considering CFTR expression differences across patient-derived organoids for the applicability of ELX-02 as a potential therapeutic option for cystic fibrosis patients with nonsense alleles.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is
Quidel Corporation Joins Global Lyme Alliance as Sponsor for the GLA ‘Fight Lyme With Avril Lavigne and Friends’ Virtual Concert Oct. 24
As part of its commitment to help educate Americans on the perils of Lyme disease, Quidel Corporation announced today that it will be one of the sponsors of the inaugural Global Lyme Alliance (GLA) “#FightLyme With Avril Lavigne & Friends” concert being held on Oct. 24. Quidel is the diagnostic health care manufacturer behind the industry’s most rapid and reliable in-office test for Lyme disease, the Sofia 2 Lyme FIA test.
“The Global Lyme Alliance has been a passionate and important partner for Quidel in our fight against Lyme disease,” said Judi Tilghman, Ph.D., vice president of technology assessment at Quidel. “Over the years they have helped fund the most urgent and promising research in the field, while expanding education and awareness programs for the general public and physicians. We’re honored to be their partner for this wonderful upcoming event.”
Being held in lieu of its annual gala, GLA will be presenting the inaugural #FightLyme With Avril & Friends virtual concert featuring Avril Lavigne, Rob Thomas, OneRepublic, Alessia Cara and host Wilmer Valderrama. The concert is designed to raise awareness and funds for GLA and The Avril Lavigne Foundation in support of their fight to conquer Lyme disease and other tick-borne diseases through research, education, awareness and patient services. Both Lavigne and Thomas have experienced Lyme disease on a personal level, and Lavigne is also a GLA board member who has been extremely vocal about the fight against Lyme disease.
The Oct. 24 concert will begin at 8 p.m. Eastern Time. Tickets can be purchased and more information is available at https://tinyurl.com/y54dn89a. More information on the Global Lyme Alliance can be found at GLA.org.
Lyme disease afflicts as many as 400,000 Americans every year and can lead to a number of serious, life-threatening problems if not caught early. Leading the way in Lyme disease testing is Quidel’s innovative Sofia® 2 Lyme FIA test. This test provides a patient as well as his or her physician with indicative results within minutes as opposed to days, which has historically been the norm. Performed in the privacy of a doctor’s office or local clinic, it is also the only test that can get results from a simple finger prick of blood. Given that the vast majority of patients tested are negative, not having to wait days for test results allows physicians and nurse practitioners to more rapidly treat those patients with positive results while more quickly pursuing other diagnosis and treatment for those who test negative.
About Quidel Corporation
Quidel Corporation (Nasdaq: QDEL) is a leading manufacturer of diagnostic solutions at the point of care delivering a continuum of rapid testing technologies that further improve the quality of health care throughout the globe. An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S. Under trusted brand names Sofia®, Solana®, Lyra®, Triage® and QuickVue®, Quidel’s comprehensive
PowerUp Fitness is usually in schools, teaching students about shapes, colors and even geometry. But COVID-19 meant they’d have to pivot to online teaching.
KNOXVILLE, Tenn. — Evelyn Price is four years old and serious about two things: drawing pictures of dogs and staying active while learning from home.
Price’s family is one of more than 2,000 participating in PowerUp Fitness, a school-based physical learning program across hundreds of schools in East Tennessee and throughout the U.S.
A global pandemic forced what would typically happen in the school gym online.
Evelyn and her mom Alicia use virtual fitness learning videos from Power Up,
a local program helping students learn while being active in school.
“All of our programs are academic, whether it’s ABC’s or geometry,” founder Stacy Baugues said.
The COVID-19 pandemic means educators need to take different approaches towards keeping kids active. Instead of typical activities, on-demand virtual videos to keep virtual students like Evelyn up and moving.
“Families can pick videos based on age or academic integration,” Baugues said.
She said that is important to combat learning loss, but it’s also important to keep kids moving in a time when many are learning from home. Experts said that she is not wrong.
Since the pandemic began, studies everywhere from the University of California to the National Library of Medicine show kids are less active right now and Baugues said there are ways communities can change that.
“They can have lots of fun and get moving and get learning together,” she said.
That is something that is important for Evelyn’s mom, Alicia, too.
“While the pandemic is a very stressful time this helps bring some light to it quite frankly,” she said.
Power Up Fitness is currently offered in several East Tennessee schools like Oak Ridge and Lenoir City. Families can also find it at the YMCA and Centro Hispano.
RELATED: Students leap into learning at Lenoir City Elementary with PowerUp Fitness
RELATED: Keeping Kids Connected: Top 5 helpful study apps and websites for students
ObsEva SA Presented Two Late-Breaking Posters at the ASRM 2020 Virtual Scientific Congress October 17-21
Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of two posters at the ASRM 2020 Virtual Scientific Congress and Expo during the first ever Late-Breaking Abstract Poster Session.
Late-breaking poster – P-931: Linzagolix may address the long-term treatment needs of women with uterine fibroids who have contraindications to hormonal add-back therapy: results from two Phase 3 randomized clinical trials
Dr. Linda Bradley, Professor of Ob/Gyn and Reproductive Biology and Vice Chair, Ob/Gyn and Women’s Health Institute, Cleveland Clinic OH, is lead author for a late-breaking poster, which discusses the potential for the low-dose (100 mg) of linzagolix, a once daily oral GnRH antagonist, to fill an unmet need for medical treatment of uterine fibroids in women who cannot or prefer to avoid hormonal add-back therapy (ABT). CDC data suggest that up to 50% of women with uterine fibroids may have a contraindication to ABT. Because linzagolix is the only oral GnRH antagonist being developed with a low-dose, no add-back therapy option, it has the potential to address the unique needs of black women, who are both disproportionately affected with uterine fibroids and are more likely to have contraindications to ABT.
Late-breaking poster – P-930: Efficacy and Safety of Linzagolix for the Treatment of Heavy Menstrual Bleeding Due to Uterine Fibroids: Results from Two Phase 3 Randomized Clinical Trials
The second late-breaking poster, with lead author Dr. Elizabeth Stewart, Professor of Obstetrics and Gynecology and Chair of the Division of Reproductive Endocrinology, Mayo Clinic MN, presented results from PRIMROSE 1 and PRIMROSE 2, the two positive Phase 3 clinical trials, which support the potential best-in-class efficacy of linzagolix in the treatment of uterine fibroids.
The related abstracts are scheduled to be published online in the Fertility and Sterility Abstract Supplement in October 2020.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving embryo transfer outcomes following in vitro fertilization. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
Yselty® (linzagolix) is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product. Linzagolix is not currently approved anywhere in the world.
Yselty® is a registered trademark owned by Kissei for use by ObsEva. Yselty® is not yet approved for use anywhere in
Phosplatin Therapeutics Announces Presentation of Research into PT-112 Mechanism of Action at the 32nd EORTC-NCI-AACR Virtual Symposium
NEW YORK, Oct. 20, 2020 /PRNewswire/ — Phosplatin Therapeutics LLC, a clinical stage pharmaceutical company focused on oncology therapeutics, today announced that data revealing novel mechanistic attributes of its lead candidate PT-112, an immunogenic cell death (ICD) inducer under Phase 2 development, will be presented at the 32nd Symposium of the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) taking place virtually from October 24-25.
PT-112, A First-In-Class Pyrophosphate-Platinum Conjugate, Selectively Targets Highly Glycolytic Tumor Cells (catalog number 188)
Saturday, October 24, 2020 on EORTC-NCI-AACR symposium site and on the Phosplatin Therapeutics web site
New Drugs Poster Session (code 380)
A. Anel, University of Zaragoza /Aragón Health Research Institute, Biochemistry and Molecular and Cell Biology, Zaragoza, Spain
Building upon prior publication of the ICD effects of PT-112, the body of work to be presented is part of an effort to understand the metabolic pathways and cellular targets affected by PT-112 upstream of ICD initiation. “The data to be reported at the 32nd EORTC-NCI-AACR Virtual Symposium advance the body of knowledge around PT-112’s pleiotropic mechanism of action and provide valuable information on further potential clinical applications of PT-112. As we continue our clinical study of this unique compound in patients with challenging cancers, such insights are important,” said Robert Fallon, co-founder and chief executive officer, Phosplatin Therapeutics. “We are pleased to co-present this body of work under our fruitful collaboration with the Anel lab at the University of Zaragoza, Spain.”
PT-112 is a novel small molecule conjugate of pyrophosphate that possesses a unique pleiotropic mechanism of action that promotes immunogenic cell death (ICD), through the release of damage associated molecular patterns (DAMPs) that bind to dendritic cells and lead to downstream immune effector cell recruitment in the tumor microenvironment. PT-112 represents the best-in-class small molecule inducer of this immunological form of cancer cell death and is currently under Phase II development. The ﬁrst in-human study of PT-112 demonstrated an attractive safety proﬁle and evidence of long-lasting responses among heavily pre-treated patients and won “Best Poster” within the Developmental Therapeutics category at the ESMO 2018 Annual Congress. The novelty of PT-112’s pyrophosphate moiety also results in osteotropism, or the propensity of the drug to reach the mineralized bone. This property is of interest in cancer types that originate in or metastasize to the bone. The combination Phase Ib study of PT-112 with PD-L1 checkpoint inhibitor avelumab in solid tumors was reported in an oral presentation at the ESMO 2020 Virtual Congress.
About Phosplatin Therapeutics
Phosplatin Therapeutics is a privately held, clinical stage pharmaceutical company that holds exclusive global license to phosphaplatins, a family of small molecules rationally designed to circumvent the mechanisms of drug resistance and toxicity commonly associated with chemotherapeutic regimens. The company’s lead candidate, PT-112, is a novel chemical entity under clinical development that exhibits a unique
Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of a poster at the ASRM 2020 Virtual Scientific Congress and Expo.
Poster number # P-482: The Effect of the Oral Oxytocin Antagonist, Nolasiban, On Pregnancy Rates in Women Undergoing Embryo Transfer Following IVF
Dr. Georg Griesinger, Professor at Luebeck University, Germany, and chair of the Department of Gynecological Endocrinology and Reproductive Medicine, University Hospital of Schleswig-Holstein, is lead author of a poster presenting results from a meta-analysis of the clinical trials and a mechanism of action study of nolasiban, an oxytocin receptor antagonist being developed for its potential to increase pregnancy rates following in vitro fertilization (IVF). Results support the further evaluation of higher doses and/or alternate regimens of nolasiban. ObsEva is partnering with YuYuan BioScience Technology, a Chinese company, for the development of nolasiban.
The related abstract is scheduled to be published online in the Fertility and Sterility Abstract Supplement in October 2020.
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving embryo transfer (ET) outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.
Nolasiban (previously known as OBE001), is an oral oxytocin receptor antagonist which was licensed from Merck KGaA, Darmstadt, Germany, in 2013. ObsEva retains worldwide, exclusive, commercial rights (ex China).
About Assisted Reproductive Technology
Infertility affects about 10% of reproductive-aged couples, with more than two million assisted reproductive technology (ART) treatments (including IVF and intracytoplasmic sperm injection (ICSI)) performed worldwide each year. In China, more than 950,000 ART cycles (IVF, ICSI, fetal ET) were performed in 2017 (National Health Commission of the PRC, presented at the 23rd International Federation of Fertility Societies conference in Shanghai, 2019).
While the success of ART depends on multiple factors including ovarian response, fertilization, embryo quality and ET procedure, a successful pregnancy ultimately hinges on the receptivity of the uterus to accept embryo implantation. Uterine contractions at the time of ET, as well as suboptimal thickness of the uterine wall and insufficient blood flow to the uterus, may impair the implantation of the embryo.
About YuYuan Bioscience Technology
YuYuan Bioscience Technology is a leading biopharmaceutical company based in China focused on discovering, developing and commercializing innovative medicines for unmet medical needs in the assisted reproductive area. The company continues to introduce a competitive portfolio of therapeutic programs aimed at helping to bring more solutions to this field. YuYuan Bioscience has a top class leadership team with deep experience at assisted reproductive therapeutics and within
The at-home fitness industry has had an explosive year. Dumbells are sold out at major retailers, fitness streaming apps are reporting record memberships, and luxe gyms are sailing on troubled waters. All signs indicate that yoga mats on living room floors could be a mainstay for a new wave of fitness enthusiasts finding their groove during the pandemic.
Taking the matter of personal fitness into your own hands is certainly more cost effective—and these days, poses a lower risk of COVID-19 exposure than venturing into your gym. But if you’ve recently had your first foray into home fitness, there’s also a bit of a learning curve. Certain mistakes can inhibit or prolong results, cause muscle strain, or even lead to injury. So ahead, two group fitness instructors from Obé Fitness—Walter Kemp and Alex Scolari—share the most common at-home fitness mistakes they see among trainees.
Failure to Devise a Consistent (and Varied) Workout Schedule
Both trainers agree that consistency is key. In order to optimize results, you should devise a workout schedule that features a variety of workout types and targeted muscle groups—then stick to it. “Don’t let your body get too comfortable; challenge yourself and mix things up,” says Scolari. “Varying workouts will help you target your full body.” If you’re on a five workouts per week schedule, Kemp recommends scheduling in three full body classes, plus two classes that target specific muscle groups. For example, you might complete a 30 minute HIIT class three days a week, then a targeted arms class one day and a targeted abs class another day.
Skipping Rest Days
Recovery is an often overlooked part of a balanced fitness routine. “Recovery is a key aspect of training. I’d say it’s the key aspect of training,” says Kemp. “You aren’t gaining muscle or losing fat in the gym or after all your grueling at home workouts. It [happens during] your recovery process. Proper sleep and adequate protein, water, mineral, and vitamin intake are vital for not only changing one’s physique but keeping your body strong and resilient.” Scolari echoes this sentiment, but notes that a rest day doesn’t mean spending the day on the couch. Scolari works out five days a week, then uses the remaining two days to take a restorative yoga class or long walk as her recovery days.
While it can be tempting to indulge after a tough workout, Kemp underscores the importance of fueling your body properly in conjunction with your fitness routine. “Movement and effort is great, but follow that up with general lethargy and a poor diet after every workout and you have a recipe for not achieving your goals,” he says.
Skipping a Warm-Up to Save Time
According to Kemp, skipping a warm-up is one of the most common home fitness mistakes that leads to injury. “You have to get the blood flowing to the areas of your body that are about to endure the stress you’re going to give to your body during
Michigan City middle school celebrates new $100K fitness center with virtual ribbon cutting | Michigan City News
Michigan City staff appeared alongside representatives from the two other Indiana middle schools and sponsors from funding partners, Coca-Cola, Anthem Foundation, Nike and Wheels Up.
Speakers shared their own experiences with youth fitness and encouraged students today to pursue “an upward spiral of success” through healthy workout habits.
“This isn’t a Democrat or Republican issue, this is a kids issue,” Steinfeld said. “This is a kids issue. We as adults need to leave this great country of ours better than we found it and that’s why now we are all a part of this great DON’T QUIT! family.”
Krueger students, who have been learning remotely for the start of the 2020-21 school year, are likely to get their first peek at the new fitness equipment when Michigan City Area Schools transition to in-person learning next week.
About 70% of the district’s students have opted to return in person, while others will be allowed to continue remote learning.
“I’m not a big emotional guy, but man, that really, for our kids, it’s big,” physical education teacher Ryan Labis said at the Krueger ribbon cutting. “What this will do for our kids and our community is beyond words.”